With shrinking national budgets, increasing deficits, demands for welfare assistance, and economies which are struggling to recover from month long lock-downs and harsh restrictive measures, investing in the unknown is a difficult decision to make.
The best chance of success for any country is to participate in an endeavour which diversifies and broadens access to a broad portfolio of possible vaccine candidates.